The Clinical Research Office (CRO) provides numerous services to faculty and staff conducting oncology research at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) including centralized systems, education, regulatory expertise and quality assurance. Centralized systems are all easily accessible via the CRO website. These systems include an up-to-date protocol library with all approved protocols and consents, a database of all oncology research studies including study accrual and tracking of all IRB submissions, the Clinical Research Review Committee (CRC) Electronic Forum which tracks documents and meeting outcome to support the CRC, a research manual with Standard Operating Procedures, and a pharmacy orders review system for tracking pre-approved orders. Education provided by the CRO includes an introductory research course for all new research staff conducting oncology trials, continuing research education for research faculty and staff, and the """"""""Messenger"""""""" newsletter designed to keep research personnel up-to-date with policies and regulations. The CRO provides regulatory expertise in the area of FDA regulations and Investigational New Drug (IND) submissions, and oversight and guidance for all investigator-initiated, multi-site trials. Quality assurance services are an essential component of the CRO via auditing and monitoring, reviewing adverse events, and developing standard operating procedures. Other services offered to investigators include acting as a liaison with the Johns Hopkins Institutional Review Boards, outside auditors, and the SKCCC External Clinical Trials website manager (to promote open trials to the community). Each SKCCC research Program has a Program manager who has a dual reporting role to both the Research Program Directors and the CRO Manager. In 2004, the CRO received 2,401 submissions (new studies, amendments, SAEs, etc). There were 348 active studies in 2004, 76% intervention in nature. This represents a heavy load in an intense regulatory environment where there i increased scrutiny and continuous interactions with the IRB. Accruals in 2004 equaled 3,121;72% on nonintervention studies and 28% on intervention trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Marrone, Kristen A; Zhou, Xian; Forde, Patrick M et al. (2018) A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Oncologist 23:859-865
Bar-Shir, Amnon; Alon, Lina; Korrer, Michael J et al. (2018) Quantification and tracking of genetically engineered dendritic cells for studying immunotherapy. Magn Reson Med 79:1010-1019
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Johnson, Renee M; Fleming, Charles B; Cambron, Christopher et al. (2018) Race/Ethnicity Differences in Trends of Marijuana, Cigarette, and Alcohol Use Among 8th, 10th, and 12th Graders in Washington State, 2004-2016. Prev Sci :
Dean, Lorraine T; Nicholas, Lauren Hersch (2018) Using Credit Scores to Understand Predictors and Consequences of Disease. Am J Public Health 108:1503-1505
Litvak, Anya; Batukbhai, Bhavina; Russell, Stuart D et al. (2018) Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer 124:1904-1911
Kandala, Sri Kamal; Liapi, Eleni; Whitcomb, Louis L et al. (2018) Temperature-controlled power modulation compensates for heterogeneous nanoparticle distributions: a computational optimization analysis for magnetic hyperthermia. Int J Hyperthermia :1-15
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Anchoori, Ravi K; Jiang, Rosie; Peng, Shiwen et al. (2018) Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer. ACS Omega 3:11917-11929
Shanbhag, Satish; Ambinder, Richard F (2018) Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 68:116-132

Showing the most recent 10 out of 2393 publications